Design Thinking for Clinical Trials

Design Thinking is a human centered approach to innovation that helps uncover the sweet spot of opportunity where the needs of people, the possibilities of technology and the requirements for business success all converge. The application of the Design Thinking methodology (originating out of Stanford’s d.School) as a new approach to looking at solutions can lead to disruptive innovation in clinical trials for drug development. It allows for designing new ways of working, including the needs, challenges and insights about the complex world we work in.   In this discussion, we introduce the basic principals of Design Thinking and an understanding of how the methodology teaches empathy for the end user (the patients). We explore its ability to reframe questions and unleash innovative thinking as well as the "downside" of creative tension. Most importantly, we address how Design Thinking can drive more successful trials.   Hosted by Valerie Bowling, Executive Director of the Conference Forum, guests include: Kate Helber President at Infidea Agency, Past Co-Founder, The Helber Group Jen Reichuber Co-Founder & Principal at Altani Associates, Past Co-Founder, The Helber Group Komathi Stem Strategic Innovation Leader, Genentech/Roche Kate, Jen and Komathi Presented a in-person program in May 2015 in Boston. For more information on the next program, plase contact us at [email protected]